0001171843-26-001973
SEC filingUnited-Guardian, Inc. reported net sales of $10.5 million for FY 2025, a decrease from $12.2 million in FY 2024. Net income was $2.1 million, down from $3.3 million in the prior year. The decline was primarily driven by a significant reduction in cosmetic ingredient sales, which fell to 29% of total sales from 45% in 2024, while pharmaceutical sales increased to 51% from 39%. The company maintained strong profitability with an operating margin of 21.3% and generated $2.0 million in operating cash flow. Key forward-looking developments include a new distribution agreement with Brenntag Specialties for sexual wellness products, ongoing negotiations to renew the ASI distribution agreement, and expected higher R&D expenses in 2026 to support innovation.
United-Guardian reported FY 2025 net sales of $10.5 million, representing a 13.4% decrease from the $12.2 million recorded in FY 2024. Net income declined 35.2% to $2.1 million from $3.3 million in the prior year. The company maintained profitability with operating income of $2.2 million and an operating margin of 21.3%. Earnings per share were $0.46 compared to $0.71 in FY 2024. The weighted average shares outstanding remained constant at 4.6 million shares. Total assets decreased to $13.1 million from $13.8 million, while stockholders' equity stood at $11.2 million.
Revenue composition shifted significantly in FY 2025. Pharmaceutical sales increased to $5.4 million (51% of total sales) from $4.7 million (39%) in FY 2024, driven primarily by Renacidin. Cosmetic ingredient sales declined sharply to $3.0 million (29% of total sales) from $5.4 million (45%) in the prior year, reflecting the impact of the terminated ASI distribution agreement. Medical lubricant sales grew modestly to $2.1 million (20% of total sales) from $2.0 million (17%). Geographically, domestic sales accounted for 77% of total revenue ($8.1 million), while foreign sales represented 23% ($2.4 million). The company had no sales in the sexual wellness category during 2025 but is prepared to begin manufacturing and distribution in 2026.
Gross profit was $5.1 million with a gross margin of 48.7%, down from 53.0% in FY 2024. Cost of sales was $5.4 million, representing 51.3% of revenue. Operating expenses totaled $2.9 million, including $2.4 million in operating expenses and $464,000 in research and development. The operating margin was 21.3%, reflecting the company's ability to maintain profitability despite revenue declines. Other income contributed $400,000, primarily from investment income of $365,000 and net gains on marketable securities of $34,000. The effective tax rate was 20.3%, resulting in a provision for income taxes of $537,000.
The company generated $2.0 million in operating cash flow during FY 2025. Investing activities provided $175,000 in net cash, consisting of $12.9 million in proceeds from marketable securities sales offset by $13.2 million in purchases and $59,000 in property acquisitions. Financing activities used $2.8 million primarily for dividend payments. Cash and cash equivalents decreased by $625,000 to $1.3 million. The balance sheet shows total assets of $13.1 million, including $7.3 million in marketable securities and $1.6 million in accounts receivable. Total liabilities were $1.9 million, resulting in a debt-free position with stockholders' equity of $11.2 million.
Management expects research and development expenses to be higher in 2026 to support innovation and growth initiatives. The company entered into a new distribution agreement with Brenntag Specialties in January 2026 for sexual wellness products in the U.S., Canada, Mexico, and France. Negotiations continue to finalize a new distribution agreement with ASI, with a goal to complete the contract in the first half of 2026. The company faces risks from global supply chain instability, inflation, and tariffs that could impact sales volume and pricing. Pharmaceutical sales growth may be supported by recent formulary approvals from two major pharmacy benefit managers for Renacidin. The company maintains ISO 9001:2015 and EFfCI GMP certifications through 2027.